Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. The primary endpoint was clinical benefit rate (CBR), with...

Descripción completa

Detalles Bibliográficos
Autores principales: Madariaga, Ainhoa, Garg, Swati, Tchrakian, Nairi, Dhani, Neesha C., Jimenez, Waldo, Welch, Stephen, MacKay, Helen, Ethier, Josee-Lyne, Gilbert, Lucy, Li, Xuan, Rodriguez, Angela, Chan, Lucy, Bowering, Valerie, Clarke, Blaise, Zhang, Tong, King, Ian, Downs, Gregory, Stockley, Tracy, Wang, Lisa, Udagani, Smitha, Oza, Amit M., Lheureux, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017680/
https://www.ncbi.nlm.nih.gov/pubmed/36922497
http://dx.doi.org/10.1038/s41467-023-37084-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017680/
https://www.ncbi.nlm.nih.gov/pubmed/36922497
http://dx.doi.org/10.1038/s41467-023-37084-w

Ejemplares similares